Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Sarcomas are a diverse group of over 150 malignant mesenchymal tumors.
• Advanced-stage sarcomas often exhibit aggressive behavior and poor prognoses.
• Despite molecular advances, effective treatments for advanced sarcomas remain a challenge.

Purpose of the Study:

• To review the current status of immunotherapy for soft tissue sarcomas (STS).
• To evaluate the efficacy of immune checkpoint inhibitors (ICI) and adoptive cell therapies in STS.
• To discuss the role of biomarkers and combination strategies in improving immunotherapy outcomes.

Main Methods:

• Literature review of clinical trials and research on immunotherapy in STS.
• Analysis of data regarding immune checkpoint inhibitors (anti-PD1/PDL1) and adoptive immune cell therapies.
• Examination of emerging biomarkers and combination therapy approaches.

Main Results:

• Clinical trials of ICI in diverse STS subtypes demonstrated limited overall efficacy, with some responders identified.
• Emerging biomarkers show potential for patient selection and guiding treatment strategies.
• Innovative adoptive cell therapies have shown promising early results in STS.

Conclusions:

• Current immunotherapy approaches, particularly ICI, have shown modest success in STS.
• Biomarker discovery and combination therapies are crucial for enhancing treatment efficacy.
• Adoptive cell therapies represent a promising frontier for managing advanced STS.